Milestone Pharma Cuts 30% of Costs, Extends Cash to Late 2028

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) reported third-quarter 2026 net product revenue of $1.0 million for its CARDAMYST (etripamil) nasal spray, up 73% from the second quarter, and disclosed on 13 November 2026 a cost-efficiency program cutting operating expenses by approximately 30%. The Montreal- and Charlotte-based company said cash, cash equivalents and short-term investments totaled $145.4 million at 30 September 2026, versus $106.0 million at 31 December 2025, a runway it now expects to extend into late 2028. Shares traded on the Nasdaq under the ticker MIST.

Context — Why Milestone's Cost Cuts Matter Now

Milestone is a commercial-stage biopharmaceutical company whose lead asset, CARDAMYST, won FDA approval for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. That approval turned the company from a pure research operation into one carrying a field sales force, payer negotiations and patient-support infrastructure. The Q3 2026 selling, general and administrative expense line reflects that shift.

The company reported SG&A of $24.2 million for the three months ended 30 September 2026, against $7.9 million a year earlier. For the nine months, SG&A reached $67.5 million versus $32.3 million in the same 2025 period. The company attributed the increases to additional personnel costs, professional costs and other operational expenses tied to the CARDAMYST launch.

That spending curve is what the new program targets. Milestone said the measures are designed to extend its cash runway through the topline results from its Phase 3 trial of etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR), a readout the company expects in the second half of 2028. The company said the actions should be complete by the first quarter of 2027 and will incur approximately $2 million in one-time charges, primarily severance, conversion fees and workforce-reduction costs.

Two senior executives departed. Chief Financial Officer Amit Hasija and Chief Medical Officer David Bharucha left the leadership team, with Bharucha transitioning to an advisor role. Anthony Krick, the company's Vice President of Finance, was named Principal Financial and Principal Accounting Officer and will lead the finance function.

Data — What the Numbers Show

The revenue base remains small relative to the expense base. Milestone reported product revenue of $963,000 in the quarter and $1.8 million for the nine months ended 30 September 2026, against no product revenue in either 2025 period. Total Q3 revenue was $2.96 million, including $2.0 million of license and other revenue.

Metric	Q3 2026	Q3 2025
Product revenue, net	$963K	$0
R&D expense, net	$3.5M	$3.9M
SG&A expense	$24.2M	$7.9M
Net loss	$25.8M	$11.9M
Net loss per share	$0.18	$0.12

Research and development expense, net of tax credits, fell to $3.5 million from $3.9 million in the prior-year quarter, and to $10.2 million from $12.6 million over nine months. Milestone credited lower outside service costs related to drug development and research, plus lower personnel costs over the longer period.

Net loss widened to $25.8 million, or $0.18 per share, from $11.9 million, or $0.12 per share. For the nine months, net loss was $80.5 million, or $0.59 per share, versus $45.6 million, or $0.60 per share, a year earlier. The share count rose to 124,498,693 common shares outstanding at 30 September 2026 from 106,236,344 at 31 December 2025.

Commercial traction: approximately 3,400 total prescriptions written by roughly 1,600 unique prescribers since launch, with payer coverage reaching about two-thirds of commercially covered lives.

Analysis — What It Means for Biotech Investors

The commercial metrics and the cost cuts point in opposite directions, and that tension defines the MIST story. Prescription volume is growing from a small base, and payer coverage at two-thirds of commercially covered lives is the gating factor for converting prescriptions into revenue. Milestone's own framing, delivered by President and CEO Joseph Oliveto, is that the company is "better able to identify where our investments can have the greatest potential impact" as it gains market experience.

The structural change is the sales model. Milestone plans to retain its field team of approximately 45 dedicated representatives but move them from a contracted model to company employees at lower overhead, maintaining current coverage. That follows an August territory optimization that cut the field force from roughly 60 representatives to focus on top performers and accounts covering electrophysiology and highest-prescribing cardiology practices.

The financing side matters as much as the expense side. An amendment to the Note Purchase Agreement with RTW Investments LP and certain affiliates extends the payment-in-kind interest period on Milestone's convertible notes from 31 March 2027 to March 2029. Senior secured convertible notes stood at $60.2 million at 30 September 2026, and a royalty financing obligation of $82.8 million appeared on the long-term balance sheet. Total shareholders' equity swung to a deficit of $6.2 million from positive $41.8 million at year-end 2025.

The counter-argument: cutting 30% of operating expenses while a launch is still scaling risks underinvesting in the commercial infrastructure that drives the very prescription growth the runway extension depends on. Milestone is betting the retained 45-representative team plus targeted marketing and patient-support programs can carry the launch. The company also deferred non-essential short-term activities, including certain manufacturing scale-up work, while keeping the AFib-RVR Phase 3 program fully funded. Positioning is binary: holders are long a launch story with a funded catalyst, while skeptics point to a widening net loss and a balance sheet where liabilities exceed assets.

Outlook — What to Watch Next

Three catalysts anchor the next two years. First, completion of the cost-efficiency program by the first quarter of 2027, with the approximately $2 million in one-time charges hitting results before then. Second, the trajectory of CARDAMYST prescriptions, unique prescribers and payer coverage, which the company reports alongside quarterly financials. Third, topline data from the ReVeRA-301 Phase 3 trial in AFib-RVR, expected in the second half of 2028.

The runway guidance is the level to watch. Milestone now says cash, cash equivalents and short-term investments should cover operating expenses and capital expenditure into late 2028, more than one year beyond prior guidance. Any deviation in that timeline, or a slower-than-expected conversion of the two-thirds payer coverage into revenue, would pressure the thesis before the AFib-RVR readout arrives. Milestone did not disclose the specific terms of the RTW amendment beyond the extended PIK period.

Frequently Asked Questions

What does Milestone's cash runway extension mean for retail investors?

It changes the financing clock. Milestone said its $145.4 million in cash, cash equivalents and short-term investments at 30 September 2026 should fund operations into late 2028, more than a year past prior guidance. For a clinical-stage company, that pushes any need to raise capital beyond the AFib-RVR Phase 3 topline readout expected in the second half of 2028, removing near-term dilution pressure that typically weighs on small biotech shares.

Why did Milestone's net loss widen in Q3 2026?

The loss reflects launch spending, not research. SG&A jumped to $24.2 million from $7.9 million a year earlier on CARDAMYST commercial personnel, professional costs and operational expenses, while R&D actually fell to $3.5 million from $3.9 million. Net loss reached $25.8 million, or $0.18 per share, versus $11.9 million, or $0.12 per share, in the prior-year quarter. The announced 30% operating-expense reduction targets that commercial cost base.

What is the AFib-RVR opportunity Milestone is funding?

Milestone is developing etripamil nasal spray in Phase 3 for atrial fibrillation with rapid ventricular rate, or AFib-RVR, through the ReVeRA-301 trial. The company estimates an addressable patient population of approximately 3 to 4 million in the United States, roughly 3 to 4 times the size of the PSVT population CARDAMYST is already approved to treat. Topline data are expected in the second half of 2028, and Milestone said the program remains fully funded.

Bottom Line

Milestone is trading near-term commercial spending for a funded runway past its 2028 AFib-RVR readout.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.